--- title: "Pre-market hot trades in US stocks: ProQR Therap down 9.78% pre-market; Americas Car Mart down 8.46% pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/290956243.md" description: "ProQR Therap pre-market down 9.78%; Americas Car Mart pre-market down 8.46%; Inlif pre-market up 96.00%; Triller pre-market up 87.56%; INVO Fertility pre-market up 50.00%" datetime: "2026-06-26T11:12:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/290956243.md) - [en](https://longbridge.com/en/news/290956243.md) - [zh-HK](https://longbridge.com/zh-HK/news/290956243.md) generator: "portal-rs" --- # Pre-market hot trades in US stocks: ProQR Therap down 9.78% pre-market; Americas Car Mart down 8.46% pre-market **Pre-market Hot Trades in US Stocks** ProQR Therapeutics is down 9.78% in pre-market trading. Based on recent key news: 1. On June 25, ProQR Therapeutics announced a $50 million underwritten registered direct offering at a price of $1.81 per share, leading to a drop in stock price. The company plans to use the proceeds for research and clinical development activities, working capital, capital expenditures, and other general corporate purposes. According to Benzinga, ProQR's stock price fell 12.71% to $1.58. 2. On June 25, ProQR reached an agreement with Eli Lilly to sell 5.1 million shares of common stock at a price of $1.81 per share, raising $9.2 million. This move aims to support the company's research and clinical development plans. 3. On June 25, ProQR announced positive Phase 1 target participation data for AX-0810, showing good safety and an eight-week half-life. This news failed to boost the stock price as concerns about the company's financial condition persist. The biotechnology industry is facing funding pressures, and market volatility is increasing. Americas Car Mart is down 8.46% in pre-market trading. Based on recent key news: 1. On June 23, the board of directors of Americas Car Mart underwent significant changes, appointing independent directors focused on restructuring and establishing a special committee for strategic alternatives. This move aims to address liquidity pressures and explore financing, restructuring, and acquisition options, leading to increased uncertainty about the company's future and putting pressure on the stock price. 2. On June 23, the company's Chief Financial Officer announced their resignation, and a senior capital markets professional was appointed as their successor. This personnel change reflects stability issues in the company's leadership during a high-risk balance sheet and strategic transition period, further exacerbating investor concerns. 3. On June 19, the company signed an agreement with Silver Point Finance to maintain liquidity and conduct a strategic review. This move indicates that the company is actively seeking ways to address financial pressures, which may affect the interests of shareholders and creditors, leading to stock price volatility. Liquidity pressures are intensifying, and market sentiment is cautious. **Top Gainers in Pre-market US Stocks** Inlif is up 96.00% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Triller is up 87.56% in pre-market trading. Based on recent key news: 1. On June 26, Triller announced the acquisition of exposure to SpaceX shares for approximately $411.3 million. This move is seen as a strategic treasury asset, driving a significant increase in stock price. Source: MT Newswires 2. On June 26, Triller's stock price surged over 326% during the trading session, with trading volume skyrocketing to 160 million shares, far exceeding the three-month average trading volume. Source: Benzinga On June 25th, Triller CEO stated that SpaceX is one of the most outstanding companies of this generation, and the acquisition provides meaningful market exposure for the company. Source: GlobeNewswire. Market interest in tech stocks has increased, with significant capital inflows. INVO Fertility pre-market rose by 50.00%. Based on recent key news: 1. On June 25th, INVO Fertility released its latest financial report, showing that its quarterly performance fell short of expectations. The company's earnings per share for the first quarter of 2026 were -$3.38, far below the expected -$1.25. This news raised concerns in the market about its future profitability. 2. On June 23rd, Wall Street analysts set a 12-month target price for INVO Fertility at $20.00, approximately 92.5% higher than its recent closing price of $1.50. This optimistic target price may have boosted investor confidence, driving the stock price up. 3. On June 26th, INVO Fertility's technical sentiment signal indicated a strong sell. However, despite the poor technical outlook, the market still holds some expectations for its business model and expansion plans, which may be one of the reasons for the stock price increase. The medical device industry has performed strongly recently, attracting high investor attention ### Related Stocks - [PRQR.US](https://longbridge.com/en/quote/PRQR.US.md) - [CRMT.US](https://longbridge.com/en/quote/CRMT.US.md) - [INLF.US](https://longbridge.com/en/quote/INLF.US.md) - [ILLR.US](https://longbridge.com/en/quote/ILLR.US.md) - [IVF.US](https://longbridge.com/en/quote/IVF.US.md) ## Related News & Research - [16:17 ETRosen Law Firm Encourages America's Car-Mart, Inc. Investors to Inquire About Securities Class Action Investigation - CRMT](https://longbridge.com/en/news/296825223.md) - [Amidst a Big Addressable Market, SpaceX Has Ample Scope for Sustained Growth](https://longbridge.com/en/news/297062883.md) - [SpaceX disses and Eminem remixes: Inside David Einhorn's latest Greenlight letter](https://longbridge.com/en/news/296801532.md) - [SpaceX Is Spending Like a Foundry Before It Owns One. What SPCX Holders Should Watch.](https://longbridge.com/en/news/296952987.md) - [‘Cool Your Rockets,’ Says Investor About SpaceX Stock](https://longbridge.com/en/news/296929242.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**